Drug Profile
Research programme: ICOS-CD28 dual agonists - Alpine Immune Sciences
Alternative Names: dual ICOS/CD28 agonist; ICOSL vIgD; V-mAb localised ICOS/CD28 agonist; V-mAbs; vIgD localised ICOS/CD28 agonistLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Alpine Immune Sciences
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD28 antigen stimulants; Inducible T-cell co-stimulator protein agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer